Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.49M | -12.65M | -16.71M | -6.36M | -8.74M |
| Total Depreciation and Amortization | 134.90K | 90.10K | 72.80K | 63.00K | 55.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -118.70K | -386.60K | 7.14M | 90.70K | 1.85M |
| Change in Net Operating Assets | 1.38M | 2.80M | -231.60K | 1.70M | -1.48M |
| Cash from Operations | -13.09M | -10.15M | -9.73M | -4.51M | -8.32M |
| Capital Expenditure | -173.10K | -327.00K | -193.30K | -60.40K | -166.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -79.72M | -- | -- | -- |
| Cash from Investing | -173.10K | -80.05M | -193.30K | -60.40K | -166.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 68.58M | 1.49M | 73.90M | 239.80K |
| Repurchase of Common Stock | -1.79M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.27M | -- | -- | -- | -- |
| Cash from Financing | 7.48M | 68.58M | 1.49M | 73.90M | 239.80K |
| Foreign Exchange rate Adjustments | -284.00K | -448.20K | 33.90K | -137.30K | 552.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.07M | -22.06M | -8.40M | 69.19M | -7.69M |